Pedroletti Christophe, Lundahl Joachim, Alving Kjell, Hedlin Gunilla
Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
Pediatr Allergy Immunol. 2008 May;19(3):219-26. doi: 10.1111/j.1399-3038.2007.00613.x.
Rhinitis is common in asthmatic schoolchildren who are allergic to animal dander and constantly and indirectly exposed to these allergens in their everyday environment. As a patho-physiological linkage between nasal and bronchial inflammation has been proposed to exist, the primary objective of this study was to determine whether nasal administration of mometasone furoate (MSNF) can reduce bronchial inflammation, as reflected in the level of exhaled nitric oxide (F(E)NO) in asthmatic schoolchildren with dander allergy and mild-to-moderate rhinitis. Forty such children were assigned randomly to be treated for 4 wk with MSNF or placebo, employing a double-blind procedure. F(E)NO was the primary end-point measured and secondary end-points were nasal levels of NO, the concentration of eosinophilic cationic protein (ECP) in nasal lavage, the relative numbers of eosinophils in blood, forced expiratory volume in 1 s (FEV(1)), peak expiratory flow (PEF) and scoring of symptoms. There was no significant difference in the F(E)NO values of the treated and control groups at any time-point, whereas the nasal level of ECP was lower in the treated group compared with placebo (p = 0.05) on both days 7 and 28, and compared with baseline for the treated group (p = 0.06 on day 7, p = 0.02 on day 28). Furthermore, the mean blood eosinophil count decreased in the treated group, which also demonstrated lower scores for nasal symptoms compared with placebo, but neither of these differences were statistically significant. FEV(1), PEF and nasal levels of NO remained unchanged in both groups. Four weeks of nasal treatment with MSNF had no effect on bronchial inflammation, as reflected by exhaled NO, whereas signs of nasal and systemic eosinophil activation were reduced. Thus, nasal administration of a steroid as a strategy to reduce asthmatic inflammation remains questionable in mild-to-moderately severe cases of perennial rhinitis and asthma.
鼻炎在对动物皮屑过敏的哮喘学龄儿童中很常见,他们在日常环境中持续且间接接触这些过敏原。由于鼻和支气管炎症之间的病理生理联系已被提出,本研究的主要目的是确定糠酸莫米松(MSNF)鼻内给药是否能减轻支气管炎症,这可通过患有皮屑过敏和轻至中度鼻炎的哮喘学龄儿童呼出一氧化氮(F(E)NO)水平反映出来。四十名此类儿童采用双盲程序随机分配接受MSNF或安慰剂治疗4周。F(E)NO是主要测量终点,次要终点包括鼻内NO水平、鼻灌洗中嗜酸性阳离子蛋白(ECP)浓度、血液中嗜酸性粒细胞相对数量、一秒用力呼气量(FEV(1))、呼气峰值流量(PEF)和症状评分。在任何时间点,治疗组和对照组的F(E)NO值均无显著差异,而在第7天和第28天,治疗组的鼻内ECP水平与安慰剂相比更低(p = 0.05),与治疗组基线相比也更低(第7天p = 0.06,第28天p = 0.02)。此外,治疗组的平均血液嗜酸性粒细胞计数下降,与安慰剂相比,其鼻症状评分也更低,但这些差异均无统计学意义。两组的FEV(1)、PEF和鼻内NO水平均保持不变。MSNF鼻内治疗四周对呼出NO所反映的支气管炎症无影响,而鼻和全身嗜酸性粒细胞激活的迹象有所减少。因此,在轻至中度严重的常年性鼻炎和哮喘病例中,鼻内给予类固醇作为减轻哮喘炎症的策略仍存在疑问。